株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

非小細胞肺癌 (NSCLC):パイプライン製品の分析

Non-Small Cell Lung Cancer - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 232838
出版日 ページ情報 英文 2236 Pages
即納可能
価格
本日の銀行送金レート: 1USD=112.37円で換算しております。
Back to Top
非小細胞肺癌 (NSCLC):パイプライン製品の分析 Non-Small Cell Lung Cancer - Pipeline Review, H2 2016
出版日: 2016年12月28日 ページ情報: 英文 2236 Pages
概要

非小細胞肺癌 (NSCLC) は、最もよく見られる肺癌の一種です。肺の組織や気道の細胞から発生する癌(悪性腫瘍)です。喫煙は、肺癌の最も多い原因です。肺癌の症状は、通常、後期に見られます。兆候と症状には、持続性の咳、呼吸困難、息切れ、恒常的な胸部の痛みや不快感、血痰、疲労、虚弱、意図しない体重減少などの症状が見られます。治療には、投薬、化学療法、生活スタイルの変更などが含まれます。

当レポートでは、非小細胞肺癌に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

非小細胞肺癌の概要

治療薬の開発

非小細胞肺癌:企業で開発中の治療薬

非小細胞肺癌:大学/機関で研究中の治療薬

非小細胞肺癌:パイプライン製品の概況

非小細胞肺癌:企業で開発中の製品

非小細胞肺癌:大学/機関で研究中の製品

非小細胞肺癌の治療薬開発に従事している企業

非小細胞肺癌:治療薬の評価

薬剤プロファイル

非小細胞肺癌:休止中のプロジェクト

非小細胞肺癌:開発が中止された製品

非小細胞肺癌:製品開発のマイルストーン

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8864IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H2 2016, provides an overview of the Non-Small Cell Lung Cancer (Oncology) pipeline landscape.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer. NSCLC is a cancer (malignancy) that originates in the tissues of the lungs or the cells lining the airways. Symptoms of lung cancer usually occur in later stages of the disease. The signs and symptoms include persistent cough that may get worse over time, trouble breathing or shortness of breath, constant chest pain or discomfort, bloody phlegm or spit (sputum), fatigue and weakness and unintentional weight loss. The disease might be controlled with the help of medications, chemotherapy and modifications in lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Non-Small Cell Lung Cancer - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Non-Small Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Non-Small Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Non-Small Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 1, 45, 178, 148, 1, 16, 156, 17 and 8 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 14, 7, 37 and 7 molecules, respectively.

Non-Small Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Non-Small Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Non-Small Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Non-Small Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Non-Small Cell Lung Cancer (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Non-Small Cell Lung Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Non-Small Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Non-Small Cell Lung Cancer Overview
  • Therapeutics Development
  • Non-Small Cell Lung Cancer - Therapeutics under Development by Companies
  • Non-Small Cell Lung Cancer - Therapeutics under Investigation by Universities/Institutes
  • Non-Small Cell Lung Cancer - Pipeline Products Glance
  • Non-Small Cell Lung Cancer - Products under Development by Companies
  • Non-Small Cell Lung Cancer - Products under Investigation by Universities/Institutes
  • Non-Small Cell Lung Cancer - Companies Involved in Therapeutics Development
  • Non-Small Cell Lung Cancer - Therapeutics Assessment
  • Drug Profiles
  • Non-Small Cell Lung Cancer - Dormant Projects
  • Non-Small Cell Lung Cancer - Discontinued Products
  • Non-Small Cell Lung Cancer - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Non-Small Cell Lung Cancer, H2 2016
  • Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Development by Companies, H2 2016 (Contd..3)
  • Number of Products under Development by Companies, H2 2016 (Contd..4)
  • Number of Products under Development by Companies, H2 2016 (Contd..5)
  • Number of Products under Development by Companies, H2 2016 (Contd..6)
  • Number of Products under Development by Companies, H2 2016 (Contd..7)
  • Number of Products under Development by Companies, H2 2016 (Contd..8)
  • Number of Products under Development by Companies, H2 2016 (Contd..9)
  • Number of Products under Development by Companies, H2 2016 (Contd..10)
  • Number of Products under Development by Companies, H2 2016 (Contd..11)
  • Number of Products under Development by Companies, H2 2016 (Contd..12)
  • Number of Products under Development by Companies, H2 2016 (Contd..13)
  • Number of Products under Development by Companies, H2 2016 (Contd..14)
  • Number of Products under Development by Companies, H2 2016 (Contd..15)
  • Number of Products under Development by Companies, H2 2016 (Contd..16)
  • Number of Products under Development by Companies, H2 2016 (Contd..17)
  • Number of Products under Development by Companies, H2 2016 (Contd..18)
  • Number of Products under Development by Companies, H2 2016 (Contd..19)
  • Number of Products under Development by Companies, H2 2016 (Contd..20)
  • Number of Products under Development by Companies, H2 2016 (Contd..21)
  • Number of Products under Development by Companies, H2 2016 (Contd..22)
  • Number of Products under Development by Companies, H2 2016 (Contd..23)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Number of Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Development by Companies, H2 2016 (Contd..3)
  • Products under Development by Companies, H2 2016 (Contd..4)
  • Products under Development by Companies, H2 2016 (Contd..5)
  • Products under Development by Companies, H2 2016 (Contd..6)
  • Products under Development by Companies, H2 2016 (Contd..7)
  • Products under Development by Companies, H2 2016 (Contd..8)
  • Products under Development by Companies, H2 2016 (Contd..9)
  • Products under Development by Companies, H2 2016 (Contd..10)
  • Products under Development by Companies, H2 2016 (Contd..11)
  • Products under Development by Companies, H2 2016 (Contd..12)
  • Products under Development by Companies, H2 2016 (Contd..13)
  • Products under Development by Companies, H2 2016 (Contd..14)
  • Products under Development by Companies, H2 2016 (Contd..15)
  • Products under Development by Companies, H2 2016 (Contd..16)
  • Products under Development by Companies, H2 2016 (Contd..17)
  • Products under Development by Companies, H2 2016 (Contd..18)
  • Products under Development by Companies, H2 2016 (Contd..19)
  • Products under Development by Companies, H2 2016 (Contd..20)
  • Products under Development by Companies, H2 2016 (Contd..21)
  • Products under Development by Companies, H2 2016 (Contd..22)
  • Products under Development by Companies, H2 2016 (Contd..23)
  • Products under Development by Companies, H2 2016 (Contd..24)
  • Products under Development by Companies, H2 2016 (Contd..25)
  • Products under Development by Companies, H2 2016 (Contd..26)
  • Products under Development by Companies, H2 2016 (Contd..27)
  • Products under Development by Companies, H2 2016 (Contd..28)
  • Products under Development by Companies, H2 2016 (Contd..29)
  • Products under Development by Companies, H2 2016 (Contd..30)
  • Products under Development by Companies, H2 2016 (Contd..31)
  • Products under Development by Companies, H2 2016 (Contd..32)
  • Products under Development by Companies, H2 2016 (Contd..33)
  • Products under Development by Companies, H2 2016 (Contd..34)
  • Products under Development by Companies, H2 2016 (Contd..35)
  • Products under Development by Companies, H2 2016 (Contd..36)
  • Products under Development by Companies, H2 2016 (Contd..37)
  • Products under Development by Companies, H2 2016 (Contd..38)
  • Products under Development by Companies, H2 2016 (Contd..39)
  • Products under Development by Companies, H2 2016 (Contd..40)
  • Products under Development by Companies, H2 2016 (Contd..41)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016 (Contd..3)
  • Non-Small Cell Lung Cancer - Pipeline by 3-V Biosciences Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by 3SBio Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by 4SC AG, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by AbbVie Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Ability Pharmaceuticals SL, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by ACEA Biosciences Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Acetylon Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Adamed Sp z oo, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Advanced Cancer Therapeutics, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Advantagene Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Allist Shanghai Pharmaceutical Technology Co Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Almac Discovery Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Altimmune Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Altor BioScience Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Amgen Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by AndroScience Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Apac Biotech Pvt Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by APO-T BV, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Aptevo Therapeutics Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Aptose Biosciences Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Argos Therapeutics Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Ariad Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by ARMO Biosciences Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Arog Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by ArQule Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Array BioPharma Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Asana BioSciences LLC, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Asterias Biotherapeutics Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by AstraZeneca Plc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by ATLAB Pharma SAS, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Atreca Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Aurigene Discovery Technologies Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Axelar AB, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Azaya Therapeutics Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Basilea Pharmaceutica Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Batu Biologics Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Bayer AG, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by BeiGene Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by BerGenBio AS, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Beta Pharma Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Bio-Path Holdings Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Biocad, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by BioCancell Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Biocon Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by BioLineRx Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Bionovis SA, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Biothera Pharmaceutical Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Blueprint Medicines Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Boston Biomedical Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Calithera Biosciences Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by CanBas Co Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cantargia AB, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by CASI Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by CBT Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Celgene Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by CellAct Pharma GmbH, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cellceutix Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cellectar Biosciences Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cellmid Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cellular Biomedicine Group Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cielo Therapeutics Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cipla Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cleave Biosciences Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Coherus BioSciences Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Corcept Therapeutics Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Corvus Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Critical Outcome Technologies Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by CSPC Pharmaceutical Group Limited, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by CTI BioPharma Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by CytImmune Sciences Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by CytomX Therapeutics Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by CytRx Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Daiichi Sankyo Company Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by DanDrit Biotech A/S, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by DEKK-TEC Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by DelMar Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Denovo Biopharma LLC, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by DiNonA Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Domainex Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by DormaTarg Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Eagle Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by EirGenix Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Eisai Co Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Eleison Pharmaceuticals LLC, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Eli Lilly and Company, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Endocyte Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by EnGeneIC Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by EntreChem SL, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Enumeral Biomedical Holdings Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Eudendron Srl, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Evotec AG, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Exelixis Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by FibroStatin SL, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Five Prime Therapeutics Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Fujifilm Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by G&E Herbal Biotechnology Co Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Ganymed Pharmaceuticals AG, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Gene Techno Science Co Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Genelux Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Genentech Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Genmab A/S, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Genocea Biosciences Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Genor BioPharma Co Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Genosco Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Genzyme Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Gilead Sciences Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Globeimmune Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by GlycaNova Norway AS, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Glycotope GmbH, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Golden Biotechnology Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Gradalis Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Grunenthal GmbH, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Halozyme Therapeutics Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Heat Biologics Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by HEC Pharm Co Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Helix BioPharma Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Hemispherx Biopharma Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Heptares Therapeutics Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by HitGen LTD, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Hutchison MediPharma Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by iCeutica Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Ideaya Biosciences Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Ignyta Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Immune Design Corp, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Immune Pharmaceuticals Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by ImmunGene Inc, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by Immunocore Ltd, H2 2016
  • Non-Small Cell Lung Cancer - Pipeline by ImmunoGen Inc, H2 2016

List of Figures

  • Number of Products under Development for Non-Small Cell Lung Cancer, H2 2016
  • Number of Products under Development for Non-Small Cell Lung Cancer - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Top 10 Routes of Administration, H2 2016
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top